These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4346935)

  • 41. Effect of different doses of methotrexate (NSC-740), cytosine arabinoside (NSC-63878), and cyclophosphamide (NSC-26271) on drug resistance in mice with L1210 leukemia.
    Schmid FA; Hutchison DJ
    Cancer Chemother Rep; 1972 Aug; 56(4):473-81. PubMed ID: 5081590
    [No Abstract]   [Full Text] [Related]  

  • 42. Induction of transplantation resistance to murine L1210 leukemia cells in BCG-primed mice by immunization with tuberculin protein-coupled L1210 cells.
    Ohno R; Kodera Y; Ogura M; Yamada H
    Gan; 1984 Feb; 75(2):187-92. PubMed ID: 6428959
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Potential antitumor agents. 21. Dialkanolamine dialkanesulfonic esters.
    Cain BF; Denny WA
    J Med Chem; 1977 Apr; 20(4):515-20. PubMed ID: 191612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
    Johnson RK; Ovejera AA; Goldin A
    Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
    [No Abstract]   [Full Text] [Related]  

  • 45. [Preliminary studies of the evaluation of immunodepressive activity in L1210 leukemia allografts in mice].
    Brambilla G; Cavanna M; Caraceni CE; Parodi S
    Boll Soc Ital Biol Sper; 1970 Mar; 46(5):230-3. PubMed ID: 5457915
    [No Abstract]   [Full Text] [Related]  

  • 46. A study of the immunosuppressive activity of methylene dimethane sulphonate (MDMS) in relation to its effectiveness as an anti-tumour agent.
    Fox BW; Gregory CJ
    Br J Cancer; 1972 Apr; 26(2):84-9. PubMed ID: 5064536
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunologic response of mice bearing leukemia L1210.
    Bonmassar E; Bonmassar A; Vadlamudi S; Goldin A
    Cancer; 1971 Jun; 27(6):1356-62. PubMed ID: 4932473
    [No Abstract]   [Full Text] [Related]  

  • 48. Antitumor activity against L1210 mouse leukemia of immunotoxins containing a monoclonal antibody to the glycolipid globotriaosylceramide.
    Junqua S; Wiels J; Tursz T; Le Pecq JB
    Immunol Lett; 1987 Jan; 14(2):167-72. PubMed ID: 3495489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of reserpine (NSC-59272)-induced hypothermia on lifespan in mouse L1210 leukemia.
    Fondy TP; Karker KL; Calcagnino C; Emlich CA
    Cancer Chemother Rep; 1974; 58(3):317-24. PubMed ID: 4841715
    [No Abstract]   [Full Text] [Related]  

  • 50. Influence of continuous infusion of cytosine arabinoside on sequencing with daunorubicin in L1210 leukemia.
    Edelstein M; Valeriote F; Vietti T
    Cancer Treat Rep; 1978 Apr; 62(4):547-8. PubMed ID: 657151
    [No Abstract]   [Full Text] [Related]  

  • 51. Dynamics of generation of antigen loss variants from L1210 murine leukemia clones detected by a tumor-specific T-cell clone.
    Nagase F; Rahman SM; Yokochi T; Kawashima K; Isobe K; Yoshida T; Nagura E; Nakashima I
    Cancer Res; 1987 Dec; 47(24 Pt 1):6494-9. PubMed ID: 3499976
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice.
    Mihich E
    Cancer Res; 1969 Apr; 29(4):848-54. PubMed ID: 4887203
    [No Abstract]   [Full Text] [Related]  

  • 53. A computer model for tumor growth and chemotherapy, and its application to L1210 leukemia treated with cytosine arabinoside (NSC-63878).
    Shackney SE
    Cancer Chemother Rep; 1970 Dec; 54(6):399-429. PubMed ID: 5527022
    [No Abstract]   [Full Text] [Related]  

  • 54. Central inhibition of cellular immunity to leukemia L1210 by isoantibody.
    Mitchell MS
    Cancer Res; 1972 Apr; 32(4):825-31. PubMed ID: 4622583
    [No Abstract]   [Full Text] [Related]  

  • 55. L1210/DTIC antigenic subline: studies at the clone level.
    Marelli O; Canti G; Franco P; Prandoni N; Ricci L; Nicolin A
    Eur J Cancer Clin Oncol; 1986 Nov; 22(11):1401-5. PubMed ID: 2435557
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Establishment of a murine leukemia L1210-specific T-cell clone displaying novel in vivo anti-tumor activity.
    Nagase F; Ueda K; Nakashima I; Kawashima K; Isobe K; Nagura E; Yamada K; Yokochi T; Hasegawa Y; Yoshida T
    Int J Cancer; 1986 Dec; 38(6):907-14. PubMed ID: 3491792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A transferable "resistance factor" from in vitro cultured MDMS-resistant Yoshida sarcoma cells.
    Szende B; Fox M; Fox BW
    Br J Cancer; 1973 Mar; 27(3):245-52. PubMed ID: 4735113
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chemotherapeutic effects of compound 593A (NSC-135758) on mouse leukemias and some transplanted animal tumors.
    Tarnowski GS; Schmid FA; Hutchison DJ; Stock CC
    Cancer Chemother Rep; 1973 Feb; 57(1):21-7. PubMed ID: 4704098
    [No Abstract]   [Full Text] [Related]  

  • 59. Modification of transplantability and tumor growth following treatment of L1210 leukemia and TA3Ha cells with macromomycin (NSC-170105).
    Lippman MM; Abbott BJ
    Cancer Chemother Rep; 1973; 57(4):501-3. PubMed ID: 4762442
    [No Abstract]   [Full Text] [Related]  

  • 60. Ultrasonic enhancement of nitrogen mustard cytotoxicity in mouse leukemia.
    Kremkau FW; Kaufmann JS; Walker MM; Burch PG; Spurr CL
    Cancer; 1976 Apr; 37(4):1643-7. PubMed ID: 1260681
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.